title: Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity.
abstract: Malignant and atypical meningiomas are resistant to standard therapies and associated with poor prognosis. Despite progress in the treatment of other tumors with therapeutic vaccines, this approach has not been tested preclinically or clinically in these tumors. Spontaneous canine meningioma is a clinically meaningful but underutilized model for preclinical testing of novel strategies for aggressive human meningioma. We treated 11 meningioma-bearing dogs with surgery and vaccine immunotherapy consisting of autologous tumor cell lysate combined with toll-like receptor ligands. Therapy was well tolerated, and only one dog had tumor growth that required intervention, with a mean follow up of 585 days. IFN-γ-elaborating T cells were detected in the peripheral blood of 2 cases, but vaccine-induced tumor-reactive antibody responses developed in all dogs. Antibody responses were polyclonal, recognizing both intracellular and cell surface antigens, and HSP60 was identified as one common antigen. Tumor-reactive antibodies bound allogeneic canine and human meningiomas, showing common antigens across breed and species. Histologic analysis revealed robust infiltration of antibody-secreting plasma cells into the brain around the tumor in posttreatment compared with pretreatment samples. Tumor-reactive antibodies were capable of inducing antibody-dependent cell-mediated cytotoxicity to autologous and allogeneic tumor cells. These data show the feasibility and immunologic efficacy of vaccine immunotherapy for a large animal model of human meningioma and warrant further development toward human trials.
authors.affiliation: Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. ande8193@umn.edu
authors.forename: Brian M
authors.initials: BM
authors.lastname: Andersen
authors.forename: G Elizabeth
authors.initials: GE
authors.lastname: Pluhar
authors.forename: Charles E
authors.initials: CE
authors.lastname: Seiler
authors.forename: Michelle R
authors.initials: MR
authors.lastname: Goulart
authors.forename: Karen S
authors.initials: KS
authors.lastname: SantaCruz
authors.forename: Melissa M
authors.initials: MM
authors.lastname: Schutten
authors.forename: Joyce P
authors.initials: JP
authors.lastname: Meints
authors.forename: M Gerard
authors.initials: MG
authors.lastname: O'Sullivan
authors.forename: R Timothy
authors.initials: RT
authors.lastname: Bentley
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Packer
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Thomovsky
authors.forename: Annie V
authors.initials: AV
authors.lastname: Chen
authors.forename: Dominik
authors.initials: D
authors.lastname: Faissler
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Hunt
authors.forename: Michael R
authors.initials: MR
authors.lastname: Olin
authors.forename: John R
authors.initials: JR
authors.lastname: Ohlfest
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity; D001921:Brain / Q000276:immunology / Q000473:pathology; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000276:immunology / Q000628:therapy*; D004285:Dogs; D008577:Meningeal Neoplasms / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D008579:Meningioma / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D014611:Vaccination
chemical_list: D000912:Antibodies, Neoplasm; D019496:Cancer Vaccines